openPR Logo

Press Releases from Reapplix (4 total)

REAPPLIX RECEIVES CODING AND REIMBURSEMENT DETAILS FOR 3C PATCH® IN THE US

3C Patch® https://3cpatch.com/ is a first-in-class advanced biologic autologous cell therapy targeting hard-to-heal diabetic foot ulcers (Birkerod, Denmark) – Reapplix, a privately-held, regenerative medicine company today announces, that coding details and reimbursement level have been set for its autologous platelet-rich plasma product 3C Patch® for the treatment of chronic non-healing diabetic wounds for up to 20 weeks. The completion of the transmittal follows the announcement of National Coverage Determination (NCD) in

A FINAL MEDICARE NATIONAL COVERAGE DETERMINATION HAS BEEN PUBLISHED ENABLING SUS …

Commercialization of this unique, breakthrough treatment for diabetic foot ulcers to be accelerated in the United States (Birkerod, Denmark) – Reapplix announces that a final National Coverage Determination (NCD) from the Centers for Medicare and Medicaid Services (CMS) has secured coverage for the company’s 3C Patch® system. The NCD describes the coverage of autologous platelet-rich plasma for the treatment of chronic, non-healing diabetic wounds for up to 20 weeks. CMS specifies

REAPPLIX ANNOUNCES APPOINTMENT OF RICHARD TWOMEY TO BOARD OF DIRECTORS

Reapplix is very pleased to be able to announce that Richard Twomey has been appointed to the Board of Directors. Mr. Twomey is a highly respected healthcare executive who for the past six years, to September 2020, has held the position of CEO and President of Mölnlycke Healthcare. Reapplix Chairman, Ulrik Spork, commented: “We are delighted to welcome Richard to our Board of Directors and are proud to have him join

REAPPLIX RECEIVES NEW REIMBURSEMENT CODING AND COMPLETES USD 22.6M EQUITY FINANC …

Reapplix announces that it has successfully received Medicare reimbursement coding instructions from the Centers for Medicare and Medicaid Services (CMS) with a national average payment rate of USD 1,622.74. The rate covers each patient visit to Hospital Outpatient Departments to receive 3C Patch® therapy for hard-to-heal diabetic foot ulcers. Reapplix also announces that it has successfully closed a USD 22.6M (DKK 150M) equity financing round, primarily to accelerate the US commercialization

Go To Page:   1 2 3 4 5 6 7 8 9 10